Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Inventiva S.A. (IVA.PA)
EUR3.87
+0.05 (+1.31%)
FR PAR Healthcare Biotechnology
Address
50 rue de Dijon 21121
Daix, FR
Daix, FR
CEO
Andrew Obenshain
Website
inventivapharma.com
IPO
2017-02-15
ISIN FR0013233012
Also trades on
Euronext Paris · IVA.PA (EUR)
London Stock Exchange · 0RNK.L (EUR)
NASDAQ Global Market · IVA (USD)
Other OTC · IVEVF (USD)
Description
Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
EUR3.87
+0.05 (+1.31%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
338.5K
Beta
0.89
Float Shares
76.85M
Free Float %
55.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.82% | -4.78% | -0.58% | -21.95% | +17.08% | +8.48% | +48.27% | +59.89% | -63.19% | -50.06% | -50.06% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
3.87
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.91
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-69.6% Q4'25: -99.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+38.3% ★ Q4'25: +75.2% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-3,640.6% Q4'25: -177,341.4% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-3,041.0% Q4'25: -274,224.1% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +158.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+212.5% Q4'25: +1,209.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.45× Q4'25: 0.46× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 3 EPS Ana. |
Dec 2027 10 Rev. Ana. 3 EPS Ana. |
Dec 2028 8 Rev. Ana. 2 EPS Ana. |
Dec 2029 7 Rev. Ana. 1 EPS Ana. |
Dec 2030 7 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.52M
est: 7.00M (-6.8%)
|
3.20M
est: 4.12M (-22.5%)
|
7.00M
est: 6.01M (+16.5%)
|
372.0K
est: 3.99M (-90.7%)
|
4.19M
est: 5.45M (-23.1%)
|
12.18M
est: 16.16M (-24.6%)
|
17.48M
est: 19.28M (-9.3%)
|
14.72M
est: 8.52M (+72.9%)
|
4.48M
est: 8.18M (-45.2%)
|
3.60M
3.46M – 3.74M
-56.0% YoY
|
24.90M
24.90M – 24.90M
+592.0% YoY
|
192.55M
190.05M – 195.05M
+673.2% YoY
|
295.70M
295.70M – 295.70M
+53.6% YoY
|
521.51M
521.51M – 521.51M
+76.4% YoY
|
| EBITDA |
-22.00M
est: -7.00M (-214.3%)
|
-32.04M
est: -4.12M (-676.9%)
|
-28.76M
est: -6.01M (-378.7%)
|
-31.78M
est: -3.99M (-695.5%)
|
-52.27M
est: -5.45M (-858.4%)
|
-57.72M
est: -16.16M (-257.2%)
|
-102.04M
est: -19.28M (-429.4%)
|
-96.70M
est: -8.52M (-1,035.2%)
|
-133.42M
est: -8.18M (-1,530.7%)
|
-3.60M
-3.74M – -3.46M
+56.0% YoY
|
-24.90M
-24.90M – -24.90M
-592.0% YoY
|
-192.55M
-195.05M – -190.05M
-673.2% YoY
|
-295.70M
-295.70M – -295.70M
-53.6% YoY
|
-521.51M
-521.51M – -521.51M
-76.4% YoY
|
| EBIT |
-22.89M
est: -7.00M (-227.1%)
|
-33.01M
est: -4.12M (-700.5%)
|
-30.21M
est: -6.01M (-402.9%)
|
-32.62M
est: -3.99M (-716.8%)
|
-53.20M
est: -5.45M (-875.4%)
|
-59.40M
est: -16.16M (-267.6%)
|
-104.64M
est: -19.28M (-442.9%)
|
-97.56M
est: -8.52M (-1,045.3%)
|
-136.33M
est: -8.18M (-1,566.3%)
|
-3.60M
-3.74M – -3.46M
+56.0% YoY
|
-24.90M
-24.90M – -24.90M
-592.0% YoY
|
-192.55M
-195.05M – -190.05M
-673.2% YoY
|
-295.70M
-295.70M – -295.70M
-53.6% YoY
|
-521.51M
-521.51M – -521.51M
-76.4% YoY
|
| Net Income |
-17.23M
est: -60.97M (+71.7%)
|
-33.62M
est: -95.53M (+64.8%)
|
-30.22M
est: -90.62M (+66.7%)
|
-33.62M
est: -60.24M (+44.2%)
|
-49.64M
est: -100.55M (+50.6%)
|
-54.27M
est: -80.08M (+32.2%)
|
-110.43M
est: -386.76M (+71.4%)
|
-184.21M
est: -260.77M (+29.4%)
|
-354.14M
est: -354.14M (+0.0%)
|
-147.29M
-156.88M – -117.21M
+58.4% YoY
|
-163.17M
-231.40M – -94.93M
-10.8% YoY
|
-96.65M
-123.43M – -69.86M
+40.8% YoY
|
-59.40M
-59.40M – -59.40M
+38.5% YoY
|
57.75M
57.75M – 57.75M
+197.2% YoY
|
| SGA |
4.12M
est: 42.61M (-90.3%)
|
4.52M
est: 25.10M (-82.0%)
|
4.51M
est: 36.57M (-87.7%)
|
9.06M
est: 24.31M (-62.7%)
|
11.52M
est: 33.20M (-65.3%)
|
15.50M
est: 98.35M (-84.2%)
|
15.61M
est: 69.76M (-77.6%)
|
17.10M
est: 30.83M (-44.5%)
|
53.89M
est: 29.61M (+82.0%)
|
13.02M
12.52M – 13.52M
-56.0% YoY
|
90.12M
90.12M – 90.12M
+592.0% YoY
|
696.82M
687.78M – 705.86M
+673.2% YoY
|
1.07B
1.07B – 1.07B
+53.6% YoY
|
1.89B
1.89B – 1.89B
+76.4% YoY
|
| EPS |
-1.11
est: -1.02 (-8.8%)
|
-1.64
est: -1.60 (-2.6%)
|
-1.28
est: -1.52 (+15.6%)
|
-0.99
est: -1.01 (+1.8%)
|
-1.27
est: -1.68 (+24.5%)
|
-1.31
est: -1.41 (+7.1%)
|
-2.43
est: -2.07 (-17.4%)
|
-3.08
est: -1.40 (-120.6%)
|
-1.90
est: -1.40 (-35.8%)
|
-0.69
-0.84 – -0.63
+50.5% YoY
|
-0.82
-1.24 – -0.51
-18.4% YoY
|
-0.52
-0.66 – -0.37
+36.9% YoY
|
-0.32
-0.32 – -0.32
+38.5% YoY
|
0.31
0.31 – 0.31
+197.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-251.43M
OE per share TTM
-2.82
Owner's Yield
-9.20%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
57.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 10 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI EMU Small Cap UCITS ETF CES1.L | 0.07% | 691.7K | 0.58% |
| 2 | iShares MSCI Europe Small-Cap ETF IEUS | 0.03% | 46.4K | 0.41% |
| 3 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.02% | 722.9K | 0.30% |
| 4 | iShares International Small-Cap Equity Factor ETF ISCF | 0.01% | 73.8K | 0.24% |
| 5 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.01% | 23.3K | 0.83% |
| 6 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.01% | 1.40M | 0.40% |
| 7 | Xtrackers MSCI Eurozone Hedged Equity ETF DBEZ | 0.01% | 5.7K | 0.45% |
| 8 | Goldman Sachs MSCI World Private Equity Return Tracker ETF GTPE | 0.00% | 1.0K | 0.50% |
| 9 | State Street SPDR MSCI World Small Cap UCITS ETF (Acc) WDSC.L | 0.00% | 41.8K | 0.45% |
| 10 | State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc) IMID.L | 0.00% | 15.6K | 0.17% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-12.0K
Shares Outstanding
139.06M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pierre Broqua | Co-Founder | 411.8K | — |
| Jean Volatier | Executive VP Finance & Corporate Social Responsibility | 355.6K | male |
| Jason A. Campagna | President of Research and Development & Chief Medical Officer | 338.2K | male |
| Martine Zimmermann | Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs | 226.1K | — |
| Andrew Obenshain | Chief Executive Officer | 152.2K | male |
| Pamela Herbster | Chief People Officer | — | female |
| Pascaline Clerc | Executive Vice President of External and Corporate Affairs | — | female |
| Susan Coles | Chief Legal Officer | — | female |
| Axel-Sven Malkomes | Chief Financial Officer | — | male |
| Eric Duranson | General Counsel | — | male |
| Nathalie Harroy | Head of Human Resources | — | female |
| Nazira Amra | Chief Commercial Strategy Officer | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IVA.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
